The U.S. Food and Drug Administration (FDA) announced on October 23, 2023, its recommendation to lift the voluntary hold on the gene therapy treatment, Elevidys, developed...
Shares of Sarepta Therapeutics (NASDAQ:SRPT) experienced a significant decline in premarket trading on October 16, 2023, following a downgrade by Barclays. The investment bank revised its...
Sarepta Therapeutics, a biotechnology firm focused on genetic medicine, experienced a notable increase in its stock value during after-hours trading. This spike followed the company’s announcement...
